These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 31539537)

  • 1. Stem cells: A path towards improved epilepsy therapies.
    Lybrand ZR; Goswami S; Hsieh J
    Neuropharmacology; 2020 May; 168():107781. PubMed ID: 31539537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The path from scientific discovery to cures for epilepsy.
    Carvill GL; Dulla CG; Lowenstein DH; Brooks-Kayal AR
    Neuropharmacology; 2020 May; 167():107702. PubMed ID: 31301334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validated animal models for antiseizure drug (ASD) discovery: Advantages and potential pitfalls in ASD screening.
    Barker-Haliski M; Steve White H
    Neuropharmacology; 2020 May; 167():107750. PubMed ID: 31469995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Making it personal: the prospects for autologous pluripotent stem cell-derived therapies.
    Blair NF; Barker RA
    Regen Med; 2016 Jul; 11(5):423-5. PubMed ID: 27346669
    [No Abstract]   [Full Text] [Related]  

  • 5. A new era of disease modeling and drug discovery using induced pluripotent stem cells.
    Suh W
    Arch Pharm Res; 2017 Jan; 40(1):1-12. PubMed ID: 27921262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening Platforms for Genetic Epilepsies-Zebrafish, iPSC-Derived Neurons, and Organoids.
    Shcheglovitov A; Peterson RT
    Neurotherapeutics; 2021 Jul; 18(3):1478-1489. PubMed ID: 34595731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systems-level framework for anti-epilepsy drug discovery.
    Johnson MR; Kaminski RM
    Neuropharmacology; 2020 Jun; 170():107868. PubMed ID: 31785261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of induced pluripotent stem cells in epilepsy.
    Hirose S; Tanaka Y; Shibata M; Kimura Y; Ishikawa M; Higurashi N; Yamamoto T; Ichise E; Chiyonobu T; Ishii A
    Mol Cell Neurosci; 2020 Oct; 108():103535. PubMed ID: 32758699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induced pluripotent stem cell technology: a decade of progress.
    Shi Y; Inoue H; Wu JC; Yamanaka S
    Nat Rev Drug Discov; 2017 Feb; 16(2):115-130. PubMed ID: 27980341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
    Liu Y; Deng W
    Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized therapeutic strategies for patients with retinitis pigmentosa.
    Zheng A; Li Y; Tsang SH
    Expert Opin Biol Ther; 2015 Mar; 15(3):391-402. PubMed ID: 25613576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concise Review: Exciting Cells: Modeling Genetic Epilepsies with Patient-Derived Induced Pluripotent Stem Cells.
    Tidball AM; Parent JM
    Stem Cells; 2016 Jan; 34(1):27-33. PubMed ID: 26373465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism-based drug discovery in zebrafish: An emerging strategy to uncover new anti-seizure therapies.
    Ibhazehiebo K; Rho JM; Kurrasch DM
    Neuropharmacology; 2020 May; 167():107988. PubMed ID: 32070912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug discovery using induced pluripotent stem cell models of neurodegenerative and ocular diseases.
    Hung SSC; Khan S; Lo CY; Hewitt AW; Wong RCB
    Pharmacol Ther; 2017 Sep; 177():32-43. PubMed ID: 28223228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stem cell contributions to neurological disease modeling and personalized medicine.
    Liang N; Trujillo CA; Negraes PD; Muotri AR; Lameu C; Ulrich H
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jan; 80(Pt A):54-62. PubMed ID: 28576415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of induced pluripotent stem cells in drug development.
    Inoue H; Yamanaka S
    Clin Pharmacol Ther; 2011 May; 89(5):655-61. PubMed ID: 21430656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induced pluripotent stem cells (iPSCs) derived from different cell sources and their potential for regenerative and personalized medicine.
    Shtrichman R; Germanguz I; Itskovitz-Eldor J
    Curr Mol Med; 2013 Jun; 13(5):792-805. PubMed ID: 23642060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress of Induced Pluripotent Stem Cell Technologies to Understand Genetic Epilepsy.
    Sterlini B; Fruscione F; Baldassari S; Benfenati F; Zara F; Corradi A
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31940887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models.
    Haggarty SJ; Silva MC; Cross A; Brandon NJ; Perlis RH
    Mol Cell Neurosci; 2016 Jun; 73():104-15. PubMed ID: 26826498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induced Pluripotent Stem Cells 10 Years Later: For Cardiac Applications.
    Yoshida Y; Yamanaka S
    Circ Res; 2017 Jun; 120(12):1958-1968. PubMed ID: 28596174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.